Skip to main content
Caplight Logo









Ractigen Therapeutics

Ractigen Therapeutics

Private
SuzhouHealthcare & Life Scienceshttps://www.ractigen.com/

Last Round

Early Funding

Jul 29, 2026

Total Funding Raised

$78M

Momentum

Top 1%

of companies Caplight tracks

Company Overview

Ractigen Therapeutics is a clinical-stage pharmaceutical company creating first-in-class therapies designed to boost expression of therapeutic genes in diseased cells using RNA activation (RNAa) technology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

RNA activationRNAasmall activating RNAsaRNAoligonucleotide therapeuticsgene upregulationRNA medicinedrug delivery platformoncology therapeuticsneurology therapeuticsgenetic disease therapyundruggable targetsCNS drug deliveryhaploinsufficiency treatmentsiRNA therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ractigen Therapeutics Comparables

Compare Ractigen Therapeutics with similar companies based on industry and business-model similarity.

Ractigen Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
MiNA Therapeutics
85%
CAMP4
73%
Shape Therapeutics
72%

Ractigen Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingJul 29, 2026
Series A ExtensionJan 27, 2022
Series AFeb 10, 2021

Key People

Founding team and executive leadership

Long-Cheng Li

Co-founder, President & CEO

Founding Team

Ractigen Therapeutics Investors

Notable investors and investment history

Ractigen Therapeutics investors
InvestorRounds
IDG CapitalEarly Funding
Boyu CapitalSeries A
Longmen CapitalEarly Funding
Hillhouse InvestmentSeries A
Huimei CapitalSeries A
CCB InternationalSeries A
SDIC Venture CapitalSeries A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 29, 2026

    $31M raised from IDG Capital and others.

  • Jan 20, 2026

    Monthly visitors increased 256% MoM.

Ractigen Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Ractigen Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Ractigen Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSuzhou
Employee Range20
Year Founded2017
Last FundingJul 29, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?